Evidence map›Paper›PMID 40617260›Full record

ArticleAntiviral research2025

Meeting report: 38th international conference on antiviral research in Las Vegas, United States of America, March 17-21, 2025.

Robert Jordan, Nancie M Archin, Valeria Cagno, Joy Y Feng, Haitao Guo, Lara J Herrero, Zlatko Janeba, Nicholas A Meanwell, Jennifer Moffat, Johan Neyts and 9 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Robert JordanBill and Melinda Gates Foundation, Seattle, WA, USA. Electronic address: robert.jordan@gatesfoundation.org.
Nancie M ArchinUniversity of North Carolina (UNC) HIV Cure Center, USA; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Valeria CagnoInstitute of Microbiology, University Hospital of Lausanne, University of Lausanne, 1011, Lausanne, Switzerland.
Joy Y FengDivision of the Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Haitao GuoDepartment of Microbiology and Immunology, Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Lara J HerreroInstitute for Biomedicine and Glycomics, Griffith University, Southport, QLD, Australia.
Zlatko JanebaInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 160 00, Prague, Czech Republic.
Nicholas A MeanwellBaruch S. Blumberg Institute, Doylestown, PA, USA; School of Pharmacy, University of Michigan, Ann Arbor, MI, USA; Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA.
Jennifer MoffatDepartment of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA.
Johan NeytsKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Antiviral Research, Leuven, Belgium.
Joana Rocha-PereiraKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virus-Host Interactions & Therapeutic Approaches (VITA) Research Group, Leuven, Belgium.
Kathie L Seley-RadtkeDepartment of Chemistry & Biochemistry, University of Maryland, Baltimore County, Baltimore, MD, USA.
Timothy P SheahanDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Rapidly Emerging Antiviral Drug Development Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jessica R SpenglerViral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Stephen R WelchViral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Xuping XieDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Drug Discovery, University of Texas Medical Branch, Galveston, TX, USA.
Hovakim ZakaryanLaboratory of Antiviral Drug Discovery, Institute of Molecular Biology of National Academy of Sciences, 0014, Yerevan, Armenia; Denovo Sciences Inc, 0060, Yerevan, Armenia.
Luis M SchangBaker Institute and Department of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
David DurantelCentre International de Recherche en Infectiologie (CIRI), Inserm_U1111, CNRS_UMR5308, Université Claude Bernard Lyon 1, F-69007, Lyon, France.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Molecular Mechanisms of HBV cccDNA FormationR01AI110762 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2016 to 2025
$3.5M
The Role of HBeAg in HBV PersistenceR01AI134818 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Haitao Guo · 2018 to 2026
$2.7M
Development of a hamster model for hepatitis B virus infectionR01AI183883 · NIAID · UTAH STATE UNIVERSITY · PI Haitao Guo, Zhongde Wang · 2024 to 2026
$2.2M
Epigenetic Regulation of HBV cccDNA TranscriptionR01AI150255 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2020 to 2024
$2.0M
HBV cccDNA and integrated DNA in HIV coinfection and HBV monoinfectionR56AI179574 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GUO, HAITAO, LAU, DARYL T · 2023 to 2023
$847k
High throughput screening and preclinical development of HBV cccDNA inhibitorsR21AI179929 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2024 to 2025
$426k
NCI NIH HHS P30 CA047904NIAID NIH HHS R01 AI110762NIAID NIH HHS R01 AI134818NIAID NIH HHS R01 AI150255NIAID NIH HHS R01 AI183883NIAID NIH HHS R21 AI179929NIAID NIH HHS R56 AI179574
6 · The paper itself

Abstract

The 38th International Conference on Antiviral Research (ICAR), sponsored by the International Society for Antiviral Research (ISAR), took place March 17-21, 2025 in Las Vegas, Nevada, USA. The annual meeting brought together leading scientists from across academia, industry, and government to present the latest advances in antiviral research. Topics included discovery and development of novel antiviral agents, innovative therapeutic approaches, vaccine technologies, host-targeted strategies, and responses to emerging and re-emerging viral threats. ICAR 2025 featured keynote talks, short oral presentations, poster sessions and special sessions to encourage discussions between attendees and foster interdisciplinary collaboration. Several events were held to support the next generation of antiviral researchers, including dedicated sessions and networking opportunities focused on mentorship and career development for students, postdoctoral fellows, and early-career scientists. Importantly, ISAR continues to serve as a cornerstone for international collaboration and innovation in antiviral science, and the society is eager to continue these efforts at the 39th ICAR, to be held in Prague, Czech Republic, from April 27-May 1, 2026.

Indexed as

Antiviral AgentsBiomedical ResearchVirus DiseasesAnimalsDrug DiscoveryHumansUnited StatesAntiviral Agents

Identifiers

PMID40617260
PMCPMC12764182

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.